en.Wedoany.com Reported - Chime Biologics announced the official launch of its GMP-2 production facility in Wuhan, China. The facility is equipped with eight 2000-liter single-use Xcellerex bioreactors from Cytiva, aiming to expand capacity to support global biopharmaceutical demand. The new facility offers flexible and efficient scale-up capabilities, supporting the entire process from discovery to delivery while maintaining consistent quality.

This expansion builds on a decade-long partnership between Cytiva and Chime Biologics. Chime's first production facility was built using the KUBio modular manufacturing platform. The KUBio platform supported Chime Biologics from early development to global commercial production, enabling a phased and efficient scale-up path tailored to customer needs.

Jimmy Wei, Board Director and CEO of Chime Biologics, stated that from the first KUBio commercial biosimilar plant in 2016 to the current GMP-2 launch and the future super factory vision, Cytiva has been a key strategic partner. As the global biopharmaceutical industry evolves toward more complex and commercialized pipelines, the next-generation manufacturing platform needs to combine flexible capacity, intelligent operations, and accelerated scalability to support the long-term success of global partners.

Allen Li, President of Cytiva China, stated that Chime Biologics' expansion reflects how flexible and scalable manufacturing solutions can help biopharmaceutical companies address growing global demand. Cytiva is committed to supporting customers in China and globally through trusted technology and consistent quality, contributing to a more resilient and diversified global biomanufacturing landscape.

Chime Biologics also announced plans to invest in a new super factory driven by artificial intelligence, equipped with over 100 2000-liter bioreactors, which is expected to become the largest single biopharmaceutical production base in China. Following the launch of the new GMP-2 facility, the proportion of revenue from markets outside China is expected to increase from approximately 50% to about 70% over the next five years. This expansion solidifies Chime Biologics' position as a global CDMO, with overseas markets already accounting for approximately 50% of total order value.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com